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Carcinosarcoma of the uterus is an uncommon and typically very aggressive neoplasm, histollogically composed of malignant epithelial and 
mesenchymal (stromal) elements.1 Uterine carcinosarl
coma is diagnosed most commonly in the seventh del
cade of life2 and shares similar risk factors and a clinical 
presentation with endometrial carcinomas.3,4 Except for 
a patient with carcinosarcoma and hereditary nonlpoll
yposis colon cancer,5 no association with a gene mutal
tion or genetic disease has been reported.
Down syndrome (DS) is the most common single 
pattern of human genetic malformation and one of the 
most common serious congenital abnormalities found 
at birth.6 DS has a particular tumor profile in which 
malignant solid tumors are underrepresented as coml
pared with the general population.7 As currently 44% 
of DS patients are alive at 60 years of age, a reduced life 
expectancy compared to the general population cannot 
explain the rarity of solid malignant tumors in adults 
with DS.8 This report describes a case of uterine carcil
nosarcoma in a woman with DS.
Case
A 38lyearlold, nulliparous, single, obese woman (BMI 
48.4 kg/m2) with DS, presented 4 years earlier to her 
primary care physicians with menorrhagia, irregular vagl
inal bleeding, abdominal pain and distention. Menstrual 
cycles commenced at the age of 13 and were irregular. 
Additional medical history included arterial hypertenl
sion, diabetes mellitus type 2 on insulin and recurrent 
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there are only a few reports of uterine cancers in women with down syndrome, whose tumor profile is 
marked by a reduced risk for solid neoplasms. there are no reports of a uterine carcinosarcoma arising in a 
woman with down syndrome. in our case, a delayed diagnosis of uterine carcinosarcoma was confirmed 
in a 38-year-old, nulliparous, single, obese woman with down syndrome, who presented with irregular 
vaginal bleeding. although uterine cancers are underrepresented in women with down syndrome, uterine 
malignancy should be considered in the differential diagnosis of abnormal vaginal bleeding. a timely and 
complete gynecological examination will preclude a delay in diagnosis.
respiratory tract infections. Her medications consisted of 
antilhypertensive drugs and insulin. She had no family 
history of malignancy. Because hormonal therapy failed 
to improve the irregular vaginal bleeding, the patient was 
admitted one year earlier to the local hospital, where the 
diagnosis of uterine fibroid was entertained. A transabl
dominal pelvic ultrasound examination confirmed the 
presence of a uterine tumor. Surgical removal of the 
uterine tumor, assumed to be a fibroid, was performed 
through a Pfannenstiel incision. At gross examination 
the surgical specimen measured 5×3×2.5 cm, appeared 
irregular, a light yellow and tan color and weighed 86.5g. 
Histological examination diagnosed uterine carcinosarl
coma. The patient was referred to a tertiary center with 
expertise in gynecologic oncology. 
At the referral center a slide review was performed. 
An immunohistochemistry assessment of samples from 
the uterine tumor revealed the following findings: cytol
keratin estrogen receptor snd vimentin positive; CD10 
focally positive; smooth muscle action and desmin 
negative; KIl67 high. The diagnosis of uterine carcil
nosarcoma with heterologous elements was confirmed. 
A whole body CT scan ruled out distal metastasis and 
local disease recurrence, but documented an intrauterl
ine mass, which was considered to be a hematoma. The 
surgical treatment plan was adjusted to the patient’s 
significant anesthesiologic risk as well as to the absence 
of lymphadenopathy on CT scan. A total hysterectomy 
and bilateral salpingoloophorectomy were performed 
using the site of the previous Pfannenstiel incision. No 
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lymph node enlargement was documented intraoperal
tively. At gross examination both ovaries had a normal 
appearance. The uterus was bulky and measured 11×8 
cm. A polypoid mass, measuring 9×4.5×4 cm, filled the 
uterine cavity, involved the endometrium of the anterior 
and posterior uterine walls and protruded through the 
cervical canal. Histological examination ascertained the 
diagnosis of uterine carcinosarcoma with lymphovasl
cular invasion, focal cervical involvement and intrapal
renchimal tumor deposits in the left ovary. No heterl
ologous elements were apparent. Adjuvant chemol and 
radiation therapy was offered, but declined by the pal
tient and her family. 
DISCUSSION
To our knowledge, this is the first report of a uterine 
carcinosarcoma in a woman with DS. A correlation 
between this neoplasm and DS has never been asl
sessed due to the paucity of the available observations. 
Uterine carcinosarcoma is rare and comprises only 1.2 
percent of uterine neoplasms,9 which are underreprel
sented in women with DS. The distribution of cancers 
in patients with DS is unique and marked by a decrease 
in the risk of solid tumors. Both earlier studies10,11 and 
two recent reviews12,13 suggested a decreased risk of 
uterine cancer in these women. This may be related to 
a particular exposure pattern in DS or to the genetic 
effect of the extra copy of chromosome 21.7 Women 
with DS experience earlier menopause,14 leading to a 
protective effect against uterine cancer. Hormonal facl
tors are unlikely to be solely responsible for this prol
tective effect. Several tumorlsuppressor genes have 
been identified on chromosome 21,7 although not yet 
any genes involved in uterine cancer.15,16 An alternal
tive hypothesis could be that in DS, protection from 
malignant transformation may be secured by increased 
spontaneous apoptosis.7 
Nulliparity, obesity and hormonal therapy are asl
sociated with uterine carcinosarcoma3,4 and should be 
considered as etiologic factors in this patient. The delay 
in the diagnosis, which impacted on this patient’s overl
all survival, is mainly due to the lack of a timely and 
complete gynecologic examination and the empiric inil
tiation of hormonal therapy. 
Almost all women with DS are nulliparous7,12 and 
overweight, and thus share two important risk factors 
for uterine neoplasm. This underscores the importance 
of a timely and complete gynecologic examination, as 
indicated, and of the need to refrain from a priori exl
clusion of uterine cancer from the differential diagnosis. 
The life expectancy of women with DS has increased 
dramatically: 44% of DS patients are reaching the sevl
enth decade of life,8 which is when the incidence of 
gynecologic malignancies peaks. This offers a compell
ling argument for periodic gynecologic examination of 
women with DS.
The unique distribution of gynecologic malignancies 
in women with DS is less evident because of the piecel
meal nature of the available information.13 However, 
considering the rarity of uterine neoplasms in DS, it is 
of great importance to report even individual cases, parl
ticularly those with treatment complications or delays.
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